Jubilant Pharmova
JUBLPHARMA
Jubilant Pharmova Market Sentiment
| Timeline | Returns | Volume |
|---|---|---|
| Daily | - | 7,804 |
| Weekly | -2.96% | 39,25,198 |
| Monthly | -4.40% | 50,68,323 |
Jubilant Pharmova Performance
| Timeline | Daily | Weekly | Monthly |
|---|---|---|---|
| JUBLPHARMA | - | -2.96% | -4.40% |
| Index | - | - | - |
| Peer Avg. | - | 5.43% | 11.51% |
Jubilant Pharmova Fundamentals
| Timeline | PE | PB | EV/EBIDTA | ROE | ROCE | Div. Yield |
|---|---|---|---|---|---|---|
| JUBLPHARMA | 46.80 | 2.99 | 9.17 | 7.27 | 8.22 | 1.40 |
| Index | 36.20 | 6.77 | 17.25 | 17.89 | 19.69 | 1.20 |
| Peer Avg. | 39.55 | 4.75 | 12.35 | 13.59 | 17.02 | 0.87 |
Jubilant Pharmova Key Metrics
| Metrics | Sales Growth | Profit Growth | ROE | ROCE |
|---|---|---|---|---|
| FY '21-22 | -48.12% | -44.11% | 7.27% | 8.22% |
| FY '20-21 | -5.83% | -25.10% | 10.95% | 11.85% |
| FY '19-20 | -21.55% | 67.50% | 13.00% | 11.15% |
Jubilant Pharmova Shareholding Pattern
Jubilant Pharmova Profit & Loss
| Metrics | Sales | Expenditure | EBITDA | PAT |
|---|---|---|---|---|
| FY '21-22 | 3,108.96 | 2,534.18 | 643.35 | 250.75 |
| FY '20-21 | 4,404.02 | 3,492.26 | 944.52 | 388.54 |
| FY '19-20 | 4,557.85 | 3,598.42 | 1,064.75 | 499.46 |
Jubilant Pharmova Peer Comparison
| Metrics | Sales | Expenditure | EBITDA | PAT |
|---|---|---|---|---|
| JUBLPHARMA | 3,108.96 | 2,534.18 | 643.35 | 250.75 |
| ORIENTELEC | 2,448.37 | 2,217.05 | 237.13 | 126.64 |
| RBA | 1,216.99 | 1,123.64 | 114.84 | -164.05 |
Jubilant Pharmova Share Price
Jubilant Pharmova Limited is an India-primarily based totally incorporated pharmaceutical company. The Company's segments encompass Pharmaceuticals, Contract Research and Development Services and Proprietary Novel Drugs. The Pharmaceuticals phase, via absolutely owned subsidiary Jubilant Pharma Limited, is engaged in manufacture and deliver of energetic pharmaceutical ingredients (APIs), strong dosage formulations, radiopharmaceuticals, hypersensitive reaction remedy merchandise and agreement production of sterile injectables and non-sterile merchandise via six production centers in India, United States and Canada and a community of about forty eight radio pharmacies withinside the United States. The Contract Research and Development Services phase affords drug discovery and improvement offerings in addition to medical records software program and carrier solutions. The Proprietary Novel Drugs phase is a patient-targeted biopharmaceutical enterprise operating to cope with unmet scientific wishes in oncology and autoimmune diseases.